

Advances in Cancer Immunotherapy™

Breast Cancer Immunotherapy: Early Data Across Agents

Leisha A. Emens, MD, PhD Professor of Medicine Director of Translational Immunotherapy For the Women's Cancer Research Center Co-Leader, Hillman Cancer Immunology/Immunotherapy Program University of Pittsburg School of Medicine

#LearnACI




Conflict of Interest

Consulting Fees: Genentech, F Hoffman La Roche, Chugai, GCPR, Gilead, Immune Onc, Shionogi, Mersana

Contracted Research: Abbvie, Astrazeneca, Bolt Therapeutics, Bristol Myers Squibb, Compugen, Corvus, CytomX, EMD Serono, Genentech, F Hoffman La Roche, Immune Onc, Maxcyte, Merck, Next Cure, Silverback, Takeda, Tempest

Other (Grants): HeritX Incorporated, NSABP Foundation, Translational Breast Cancer Research Consortium, Breast Cancer Research Foundation, National Cancer Institute, Department of Defense, Johns Hopkins University, University of California San Francisco, Cornell University, Dana Farber Cancer Institute Advances in Cancer Immunotherapy™

The Immune System and Breast Cancer



Gajewski TF Semin Oncol 2015 42: 663-71. Herbst RS et al Nature 2014 515: 568-71. Chen DS Mellman I Immunity 2013 39: 1-10. Cimino-Mathews A/Emens LA, unpublished images.


- Poor prognostic factors (ER^{neg}, PR^{neg}, high grade, LN⁺) are associated with higher T cell infiltrates at diagnosis
- Higher numbers of CD8⁺ TILs and a higher CD8+ T cell/FoxP3+ Treg ratio predict better clinical outcomes (cPR, DFS, OS), except for ER+ BC
- TNBC and HER-2+ breast cancers are high value targets for cancer immunotherapy
 - --No approved targeted therapies for TNBC
 - --Potentially synergistic targeted therapies in HER-2+ BC
- ER+ breast cancers present the challenge of transforming tumors from cold to hot

sitc

for Immunotherapy of Cance


Advances in Cancer ImmunotherapyTM Clinical versus Intrinsic Breast Cancer Subtypes

Intrinsic Breast Cancer Subtypes



#LearnACI

© 2021–2022 Society for Immunotherapy of Cancer



Prat/Perou et al Molec Oncol 2011; 25: 5-23.


Sitc Advances in Cancer ImmunotherapyTM Immunologic Features of Breast Cancer Subtypes

Breast Cancer Subtype	Clinical Phenotype	Immunologic Phenotype
Luminal A	90% ER+ 89% PR+ 14% HER-2+	Lymphocyte predominant 2.9% Median stromal TILs 10%
Luminal B	98% ER+ 82% PR+ 24% HER-2+	Median intratumoral TILs 1.5% TILs at Dx not predictive
HER-2-enriched	38% ER+ 20% PR+ 72% HER-2+	Lymphocyte predominant 11.1% Median stromal TILs 15% Median intratumoral TILs 3% TILs at Dx predictive of response
Basal-like (includes 70-80% TNBC) Kroemer G et al-Nature Med 2015 21: 1128-38.	8% ER+ 7% PR+ 7% HER-2+	Lymphocyte predominant 10.6% Median stromal TILs 20% Median intratumoral TILs 5% TILs at Dx predictive of response

Kroemer G et al. Nature Med 2015 21: 1128-38.

© 2021–2022 Society for Immunotherapy of Cancer

Targeting the PD-1 Pathway in Breast Cancer




sitc

TNBC and HER-2⁺ BC are high value targets for cancer immunotherapy:

- Higher rates of mutational complexity
- Presence of PD-1⁺ and PD-L1⁺ TIL
- Several potentially synergistic targeted therapies
 - Trastuzumab/Pertuzumab
 - TDM1, Sacituzumab
 - Bevacizumab (ex US)

ER+ breast cancers present the challenge of transforming tumors from cold to hot

Avelumab Activity in Breast Cancer Patients



Dirix L et al SABCS 2015

© 2021–2022 Society for Immunotherapy of Cancer

#LearnACI

sitc


Society for Immunotherapy of Cancer

Pembrolizumab Activity in PD-L1+ TNBC and ER+ BC

100

- ORR: 18.5%; PFS rate at 24 weeks: 23.3% (n= 27)
- 1 CR, 4 PRs, 7 SD, 3 of 5 responses ongoing

- ORR: 12%; PFS rate at 24 weeks: 20% (n=20)
- No CRs, 3 PRs, evidence of pseudoprogression



Nanda R et al. JCO 2016;34:2460. Rugo H et al. SABCS 2015.

sitc



Atezolizumab Monotherapy in Metastatic TNBC: Patient Population

Baseline Characteristics	Patients (N = 115)	Safety-Evaluable Patients
Median age (range)	53 y (29 to 82)	Received ≥ 1 dose of atezolizumab (N = 115)
ECOG PS, 0 1 2	46% 52% 2%	
Visceral metastatic sites ^a	65%	
Bone metastatic sites ^b	30%	Efficacy-Evaluable Patients
PD-L1 status on IC ^c		Had \geq 12 weeks of follow-up
IC0/1 (< 5%)	33%	(n = 113)
IC2/3 (≥ 5%)	63%	
Median prior systemic therapies (range) ^d	7 (0 to 21)	*
Anthracycline taxane	85% 94%	Objective Response– Evaluable Patients
Platinum bevacizumab	58% 21%	(n = 112)
Current line of therapy, ^e 1L 2L 3L+	17% 24% 58%	

Prior to receiving atezolizumab, most patients were heavily pretreated

 At data cutoff, median treatment duration was 2.1 mo (range, 0.0-36.6)

• Median of 4 cycles (range, 1-45)


HL, first line; 21, second line; 3L, third line. ^a Includes lung, liver, adrenal and pelvis metastatic sites. ^b Includes bone and other sites. Four patients (4%) had unknown IC status. ^d Refers to all treatment settings. ^e Refers to treatment in metastatic setting only. ©Data codoff SMarchr31m2016 rapy of Cancer Schmid P, et al. AACR 2017 Phase la Atezolizumab in TNBC

sitc

Society for Immunotherapy of Cance

Classical and Atypical Responses in TNBC Patients Treated with Atezolizumab

All Response-Evaluable Patients



 Clinical benefit was observed in some patients with RECIST v1.1 SD or PD status

Overall TNBC cohort

Criteria	Median DOR (range)	Median PFS (95% CI)
RECIST v1.1	21.1 mo (2.8 to 26.5+)	1.4 mo (1.3, 1.6)
irRC	21.1 mo (2.8 to 33.9+)	1.9 mo (1.4, 2.6)


Schmid P, et al. AACR 2017 Phase Ia Atezolizumab in TNBC

HrPR_PR_per irRC; SLD, sum of target lesion longest diameter. ^a Re-treatment period not plotted. Confirmed, investigator-assessed RECIST responses are included for patients with post-baseline tumor measurements. ©Datal codoff SMarchr3d_m2Q16crapy of Cancer

sitc

Classical and Atypical Responses in TNBC Patients Treated with Atezolizumab

Patients With RECIST v1.1 Response or Stable Disease or irRC Response




 Clinical benefit was observed in some patients with RECIST v1.1 SD or PD status


Overall TNBC cohort

Criteria	Median DOR (range)	Median PFS (95% CI)
RECIST v1.1	21.1 mo (2.8 to 26.5+)	1.4 mo (1.3, 1.6)
irRC	21.1 mo (2.8 to 33.9+)	1.9 mo (1.4, 2.6)

Schmid P, et al. AACR 2017 Phase Ia Atezolizumab in TNBC



Advances in Cancer Immunotherapy TNBC Response Rates to Atezolizumab by Subgroup



 Numerically higher ORRs were observed in IC2/3 and 1L subgroups


 irRC criteria captured non-classical responses to atezolizumab

* Objective response-evaluable patients. Four patients had unknown PD-L1 status. Confirmed, investigator-assessed responses are plotted. Patients with missing or an evaluable responses are included (16 per RECIST v1.1 and 23 per irRC). ^b ORR 95% CI was estimated using Clopper-Pearson method. Data cutoff: March 31, 2016.

© 2021–2022 Society for Immunotherapy of Cancer

Schmid P, et al. AACR 2017 Phase la Atezolizumab in TNBC

TNBC Response Rates to Atezolizumab by Subgroup



- Numerically higher ORRs were observed in IC2/3 and 1L subgroups
- irRC criteria captured non-classical responses to atezolizumab
- Best response of SD were also observed
 - DCR^b per RECIST v1.1 was 23% in all patients
 - 27% in IC2/3 patients
 - 16% in IC0/1 patients

DCR, disease control rate. ^a Objective response–evaluable patients. Four patients had unknown PD-L1 status. ^b Defined as CR + PR + SD ≥ 3 months. Confirmed investigator-assessed responses are plotted. Patients with missing or unevaluable responses are included (16 per RECIST v1.1 and 23 per irRC).

Schmid P, et al. AACR 2017 Phase la Atezolizumab in TNBC

© 2021–2022 Society for Immunotherapy of Cancer


sitc

Society for Immunotherapy of Cancer



Overall Survival by Response Status


- Median OS was 9.3 mo (95% CI: 7.0, 12.6) in all patients^a
 - Landmark OS rates (95% CI) were: 41% (31, 51) at 1 year, and 22% (12, 32) at both 2 and 3 years




• Pseudo-progression was observed in patients with RECIST PD and long-term OS

Median survival follow-up (range) was 15.2 mo (0.4+ to 36.7) in all patients, 17.0 mo (0.43+ to 36.7) in IC2/3 patients and 12.8 mo (0.8+ to 16.9) in IC0/1 patients. ^b Patients included in the Kaplan-Meier plots were alive for \geq 6 weeks. Data cutoff: March 31, 2016. © 2021–2022 Society for Immunoiherapy of Cancer

Schmid P, et al. AACR 2017 Phase Ia Atezolizumab in TNBC



Overall Survival with Atezolizumab by PD-L1 Status



		PD-L1 Status ^a			
	All Pts (n = 113)	IC2/3 (n = 71)	IC0/1 (n = 38)		
mOS (95% CI)	9.3 mo (7.0, 12.6)	10.7 mo (7.2, 14.7)	7.1 mo (5.1, 12.6)		

 Longer OS was observed in patients with higher PD-L1 IC status

^a Four patients had unknown PD-L1 status. Median survival follow-up (range) was 15.2 mo (0.4+ to 36.7) in all patients, 17.0 mo (0.43+ to 36.7) in IC2/3 patients and 12.8 mo (0.8+ to 16.9) in IC0/1 patients. Data cutoff: March 31, 2016.

Schmid P, et al. AACR 2017 Phase la Atezolizumab in TNBC

© 2021–2022 Society for Immunotherapy of Cancer

#LearnA


Society for Immunotherapy of Cancer



Society for Immunotherapy of Cancer

Association of Response and Survival with TILs

Median TIL infiltration (% tumor area) in tumors from enrolled patients defined the cutoff used for analysis



- Higher ORR and longer OS were seen with higher baseline TIL infiltration
- Similar results were observed with CD8 infiltration

Sapples unevaluable for TIL assessments (6 per RECIST v1.1 and 5 per irRC) are not included. Objective response-evaluable population includes patients with unevaluable response assessments (16 per RECIST v1.1 and 23 per irRC). Log-rank (Mantel-Cox) P value is exploratory. Data cutoff: March 31, 2016. © 2021–2022 Society for Immunotherapy of Cancer

Schmid P, et al. AACR 2017 Phase la Atezolizumab in TNBC

6.6 mo

(4.9, 10.2)

mOS

(95% CI)

12.6 mo

(10.5, NA)

Advances in Cancer ImmunotherapyTM KEYNOTE-086: Phase 2 Study of Pembrolizumab in Metastatic TNBC

Conort A: Previously Treated PD-L1 Unselected 386 patients		Previously Treated Any PD-L1 Expression Cohort A		First Line PD-L1 Selected	
screened 170 patients enrolled/treated		All (n=170)	PD-L1+ (n=105)	PD-L1- (n=64)	PD-L1+ (n=52)
 105 PD-L1 positive (61.8%) 64 PD-L1 negative (37.6%) 1 PD-L1 unknown (0.6%) 	ORR, %	4.7%	4.8%	4.7%	23.1%
	DCR, %	7.6%	9.5%	4.6%	
	CR, n	1	1	0	
PD-L1 is an imperfect biomarker. Context is important.	PR, n	7	4	3	
	SD, n	35	22	112	
# Adams S ASCO 2017					

© 2021–2022 Society for Immunotherapy of Cancer

Cobort A



Advances in Cancer Immunotherapy™

PD-1/PD-L1 Blockade in Breast Cancer

Antibody	Target	Subtype	Patients	ORR
Avelumab	PD-L1	All	168	4.8%
		PD-L1+ All	12	33.3%
		TNBC	58	8.6%
		PD-L1+ TNBC	9	44.4%
Pembrolizumab	PD-1	PD-L1+ TNBC	20	18.5%
		PD-L1+ ER+HER-2-	21	12%
Atezolizumab	PD-L1	TNBC	112	10%
		PD-L1+ TNBC	71	13%
Dirix L et al SABCS 2015 #LearnACI	Nanda R et al JCO 2016; Rugo et al SABCS 2015	34:2460		et al AACR 2015 et al AACR 2017

© 2021–2022 Society for Immunotherapy of Cancer

Society for Immunotherapy of Cancer

Advances in Cancer ImmunotherapyTM

The Major Challenges of Breast Cancer Immunotherapy Today

- Subtype framework—well established but the lines are blurred
 - Clinical subtypes
 - Intrinsic subtypes
 - Immune profiles
- Shared antigens vs. neoantigens and the T cell repertoire
- Many standard therapies with significant efficacy
- Effects of drugs on the tumor and the immune system
- Matching patients to the most relevant combinations

• Converting nonresponders to responders LearnACI


© 2021–2022 Society for Immunotherapy of Cancer



sitc


Society for Immunotherapy of Cancer

Selected Promising Combination Immunotherapies for Breast Cancer




Advances in Cancer Immunotherapy™ One Framework for Personalizing Breast Cancer Immunotherapy Patterns of T Cell Infiltration

Non-inflamed




Chemotherapy, XRT HER-2-directed antibodies Vaccines, STING agonists

Immune-Excluded



Bevacizumab Chemokine Modulators


Gajewski TF Semin Oncol 2015 42: 663-71. Herbst RS et al Nature 2014 515: 568-71. Chen DS Mellman I Immunity 2013 39: 1-10. Cimino-Mathews A/Emens LA, unpublished images. Inflamed



Anti-PD-1/PD-L1 IDO inhibition A2AR inhibition

#LearnACI © 2021–2022 Society for Immunotherapy of Cancer

Advances in Cancer Immunotherapy Mechanism-Driven Cancer Immunotherapy Combinations



#LearnACI © 2021–2022 Society for Immunotherapy of Cancer


Chen DS and Mellman I. Immunity 39:1-10, 2013

Sitc> Advances in Cancer Immunotherapy™

Atezolizumab and Nab-Paclitaxel Have Activity in mTNBC


Change in Tumor Burden Over Time with Line of Therapy

- PD-L1 unselected patients
- Atezolizumab 840 mg every 2W; Nab-paclitaxel 100 mg/m² weekly
- Confirmed ORR = 41.7%; 3 pseudoprogressors




Sams S, et al SABCS 2015 © 2021–2022 Society for Immunotherapy of Cancer





n = 15 (ORR ~ 25-28%)

sitc Advances in Cancer ImmunotherapyTM PANACEA: A Phase 1b/2 Trial of Pembrolizumab and Trastuzumab in Patients with Trastuzumab^R Metastatic HER-2+ Breast Cancer



Treat to PD, toxicity, withdrawal, or max 2 years.

© 2021–2022 Society for Immunotherapy of Cancer


sitc

CR

PR


SD

PANACEA: A Phase 1b/2 Trial of Pembrolizumab and Society for Immunotherapy Trastuzumab in Patients with Trastuzumab^R Metastatic HER-2+ Breast Cancer



PD-L1+ Cohort (n = 44)


PANACEA: A Phase 1b/2 Trial of Pembrolizumab and Trastuzumab in Patients with Trastuzumab^R Metastatic HER-2+ Breast Cancer



© 2021–2022 Society for Immunotherapy of Cancer

sitc

Advances in Cancer Immunotherapy[™] KATE2: A randomized Phase II study of atezolizumab + trastuzumab emtansine (T-DM1) vs placebo + T-DM1 in previously treated HER2+ advanced breast cancer



- Liver metastases (yes vs no)

Primary endpoint

 Investigator-assessed PFS per RECIST v1.1 (ITT)

Secondary endpoints

OS, ORR, DOR (ITT)

Exploratory endpoints

- PFS in the PD-L1+ (PD-L1 IC ≥ 1%) subgroup
- Efficacy in subgroups defined by immune-related (tumor-infiltrating lymphocytes and CD8 IHC expression) and HER2-related biomarkers

Safety endpoints


 AEs, SAEs, AEs leading to death, study discontinuation, or dose reduction and interruption

Emens LA et al SABCS 2018

©, tumor-infiltrating immune cells; LABC, locally advanced breast cancer; mBC, metastatic breast cancer; q3w, every 3 weeks; RECIST, Response Evaluation Criteria in Solid Tumors; Tx, treatment. © 2021–2022 Society for Immunotherapy of Cancer


Advances in Cancer ImmunotherapyTM Society for INTE2: PFS in ITT and PD-L1 IC+ Populations

Primary Endpoint PFS in ITT Patients



 The study did not demonstrate a meaningful PFS benefit from the addition of atezolizumab to T-DM1 in the ITT population

Primary Endpoint PFS in PD-L1+ Patients




- PFS in the PD-L1+ subgroup numerically favored atezolizumab + T-DM1 vs atezolizumab + placebo (HR, 0.60 [95% CI: 0.32, 1.11])
- The magnitude of the benefit is uncertain given the limited number of patients and the corresponding wide confidence interval of the hazard ratio

• One-year OS rate was numerically higher with the addition of atezolizumab in PD-L1 IC+ subgroup



Advances in Cancer Immunotherapy™

KATE 3 study




- Co-Primary Endpoint: PFS by investigator assessment using RECIST v1.1 and OS
- Secondary Endpoint: ORR, DOR, PFS by independent central review, PFS and OS in patients with baseline brain metastases, CNS PFS, OoL

*HER2 and PD-L1 positivity determined by central laboratory. *Patients will be followed for survival status and new anti-cancer therapy every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

LABC, locally advanced breast cancer; MBC, metastatic breast cancer; PFS, progression-free survival; OS, overall survival; ORR, objective response rate; DOR, duration of response; CNS, central nervous system; QoL, quality of life

GELATO Trial: Clinical Benefit in Lobular Cancer




Biopsy metastatic lesion + blood sampling Carboplatin, AUC 1.5 Atezolizumab, 1200 mg Simon's two-stage design: n=22 in stage 1 At least 3 patients need to be progression-free at 6 months

Main inclusion criteria

- Metastatic ILC with negative or aberrant E-cadherin
- ER+ disease: endocrine treatment resistant
- Max. 2 lines of palliative chemotherapy
- LDH < 2 ULN

sitc


FLearnACI



sitc

Society for Immunotherapy of Cancer

Host Factors May Influence the Response to Breast Cancer Immunotherapy





Conclusions

- Breast cancer can be immunogenic, most breast tumors are not
- Multiple layers of regulation within the TME shut down tumor immunity
- Standard cancer therapies can augment the activity of immunotherapies
- The future is in combination immunotherapies which should have synergistic clinical activity but may come at a toxicity cost
- We need to do smart trials elucidating immunologic mechanisms of response and resistance in patients